170 related articles for article (PubMed ID: 28173790)
1. DCIS and axillary nodal evaluation: compliance with national guidelines.
Mitchell KB; Lin H; Shen Y; Colfry A; Kuerer H; Shaitelman SF; Babiera GV; Bedrosian I
BMC Surg; 2017 Feb; 17(1):12. PubMed ID: 28173790
[TBL] [Abstract][Full Text] [Related]
2. The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ.
Coromilas EJ; Wright JD; Huang Y; Feldman S; Neugut AI; Chen L; Hershman DL
JAMA Oncol; 2015 Jun; 1(3):323-32. PubMed ID: 26181180
[TBL] [Abstract][Full Text] [Related]
3. The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based study.
Holm-Rasmussen EV; Jensen MB; Balslev E; Kroman N; Tvedskov TF
Eur J Cancer; 2017 Dec; 87():1-9. PubMed ID: 29096155
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Surgical Trends for Axillary Lymph Node Management in Patients with Ductal Carcinoma In Situ Using the NSQIP Database: Are We Following National Guidelines?
Pyfer BJ; Jonczyk M; Jean J; Graham RA; Chen L; Chatterjee A
Ann Surg Oncol; 2020 Sep; 27(9):3448-3455. PubMed ID: 32232706
[TBL] [Abstract][Full Text] [Related]
5. Trends and clinicopathological predictors of axillary evaluation in ductal carcinoma in situ patients treated with breast-conserving therapy.
Huang NS; Si J; Yang BL; Quan CL; Chen JJ; Wu J
Cancer Med; 2018 Jan; 7(1):56-63. PubMed ID: 29271113
[TBL] [Abstract][Full Text] [Related]
6. Axillary evaluation in ductal cancer in situ of the breast: challenging the diagnostic accuracy of clinical practice guidelines.
Karakatsanis A; Charalampoudis P; Pistioli L; Di Micco R; Foukakis T; Valachis A;
Br J Surg; 2021 Sep; 108(9):1120-1125. PubMed ID: 34089583
[TBL] [Abstract][Full Text] [Related]
7. Ductal carcinoma in situ: value of sentinel lymph node biopsy.
Sakr R; Barranger E; Antoine M; Prugnolle H; Daraï E; Uzan S
J Surg Oncol; 2006 Oct; 94(5):426-30. PubMed ID: 16967457
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with lymph node assessment in ductal carcinoma in situ: analysis of 1988-2002 seer data.
Porembka MR; Abraham RL; Sefko JA; Deshpande AD; Jeffe DB; Margenthaler JA
Ann Surg Oncol; 2008 Oct; 15(10):2709-19. PubMed ID: 18483831
[TBL] [Abstract][Full Text] [Related]
9. Utilization of Axillary Surgery for Patients With Ductal Carcinoma In Situ: A Report From the National Cancer Data Base.
Miller ME; Kyrillos A; Yao K; Kantor O; Tseng J; Winchester DJ; Shulman LN
Ann Surg Oncol; 2016 Oct; 23(10):3337-46. PubMed ID: 27334212
[TBL] [Abstract][Full Text] [Related]
10. Time trends and inter-hospital variation in treatment and axillary staging of patients with ductal carcinoma in situ of the breast in the era of screening in Southern Netherlands.
van Steenbergen LN; Voogd AC; Roukema JA; Louwman WJ; Duijm LE; Coebergh JW; van de Poll-Franse LV
Breast; 2014 Feb; 23(1):63-8. PubMed ID: 24291376
[TBL] [Abstract][Full Text] [Related]
11. [A single-center retrospective study on axillary evaluation in 1 557 breast ductal carcinoma in situ patients between 2006 and 2016].
Si J; Quan CL; Mo M; Guo R; Su YH; Yang BL; Chen JJ; Shao ZM; Wu J
Zhonghua Wai Ke Za Zhi; 2019 Sep; 57(9):681-685. PubMed ID: 31474060
[No Abstract] [Full Text] [Related]
12. Sentinel lymph node biopsy in the management of ductal carcinoma in situ.
Zujewski J; Eng-Wong J
Clin Breast Cancer; 2005 Aug; 6(3):216-22. PubMed ID: 16137431
[TBL] [Abstract][Full Text] [Related]
13. Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy.
Mittendorf EA; Arciero CA; Gutchell V; Hooke J; Shriver CD
Curr Surg; 2005; 62(2):253-7. PubMed ID: 15796952
[TBL] [Abstract][Full Text] [Related]
14. Tumor size as predictor of microinvasion, invasion, and axillary metastasis in ductal carcinoma in situ.
Maffuz A; Barroso-Bravo S; Nájera I; Zarco G; Alvarado-Cabrero I; Rodríguez-Cuevas SA
J Exp Clin Cancer Res; 2006 Jun; 25(2):223-7. PubMed ID: 16918134
[TBL] [Abstract][Full Text] [Related]
15. The value of sentinel lymph node biopsy in ductal carcinoma in situ (DCIS) and DCIS with microinvasion of the breast.
van la Parra RF; Ernst MF; Barneveld PC; Broekman JM; Rutten MJ; Bosscha K
Eur J Surg Oncol; 2008 Jun; 34(6):631-5. PubMed ID: 17851019
[TBL] [Abstract][Full Text] [Related]
16. Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy.
Chin-Lenn L; Mack LA; Temple W; Cherniak W; Quinn RR; Ravani P; Lewin AM; Quan ML
Ann Surg Oncol; 2014 Jan; 21(1):66-73. PubMed ID: 24046105
[TBL] [Abstract][Full Text] [Related]
17. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer.
Bilimoria KY; Bentrem DJ; Hansen NM; Bethke KP; Rademaker AW; Ko CY; Winchester DP; Winchester DJ
J Clin Oncol; 2009 Jun; 27(18):2946-53. PubMed ID: 19364968
[TBL] [Abstract][Full Text] [Related]
18. The role of sentinel lymph node biopsy in ductal carcinoma in situ.
Moran CJ; Kell MR; Kerin MJ
Eur J Surg Oncol; 2005 Dec; 31(10):1105-11. PubMed ID: 16084681
[TBL] [Abstract][Full Text] [Related]
19. Sentinel lymph node biopsy for ductal carcinoma in situ: an evolving approach at the University of Florida.
Camp R; Feezor R; Kasraeian A; Cendan J; Schell S; Wilkinson E; Copeland E; Lind S
Breast J; 2005; 11(6):394-7. PubMed ID: 16297082
[TBL] [Abstract][Full Text] [Related]
20. Factors predicting microinvasion in Ductal Carcinoma in situ.
Ozkan-Gurdal S; Cabioglu N; Ozcinar B; Muslumanoglu M; Ozmen V; Kecer M; Yavuz E; Igci A
Asian Pac J Cancer Prev; 2014; 15(1):55-60. PubMed ID: 24528005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
